Patents by Inventor Guojun Lang

Guojun Lang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Molecule Specifically Binding to CLDN18.2
    Publication number: 20240092891
    Abstract: Provided are a molecule specifically binding to CLDN18.2, the molecule comprising an immunoglobulin single variable domain, a nucleic acid molecule encoding the molecule specifically binding to CLDN18.2, and an expression vector and a host cell for expressing the molecule specifically binding to CLDN18.2; further provided are a method for producing the molecule specifically binding to CLDN18.2 and use thereof for treating or preventing conditions associated with CLDN18.2.
    Type: Application
    Filed: November 23, 2021
    Publication date: March 21, 2024
    Inventors: Yongcong Tan, Guojun Lang, Chanjuan Liu, Xintian Yan
  • HUMANIZED MONOCLONAL ANTIBODY TARGETING BCMA AND HAVING HUMAN MONKEY CROSS-REACTIVITY
    Publication number: 20240052048
    Abstract: Provided is an isolated monoclonal antibody targeting B-cell maturation antigen (BCMA), the antibody can bind to both human BCMA and monkey BCMA. Also provided are a nucleic acid encoding the antibody, a method for producing the antibody, and a pharmaceutical composition comprising the antibody.
    Type: Application
    Filed: September 25, 2020
    Publication date: February 15, 2024
    Applicant: SUZHOU QIN PHARMACEUTICALS CO., LTD.
    Inventors: Ning LI, Guoqing CAO, Guojun LANG, Chanjuan LlU, Yuhao HU
  • ANTI-B7-H3 ANTIBODY AND PREPARATION THEREFOR AND USE THEREOF
    Publication number: 20230212294
    Abstract: Provided are an anti-B7-H3 antibody and preparation thereof and a use thereof. Further provided is a drug conjugate and recombinant protein containing the antibody. The antibody of the present invention can be effectively endocytosed by cells, and an antibody-conjugated drug prepared by using the antibody of the present invention shows a tumor inhibition effect.
    Type: Application
    Filed: June 2, 2021
    Publication date: July 6, 2023
    Inventors: Liyuan ZHU, Wenyi WANG, Guojun LANG, Min DENG
  • PD-L1 BINDING MOLECULE
    Publication number: 20230002494
    Abstract: The present application provides an isolated PD-L1 binding molecule, specifically, an isolated PD-L1 single-domain antibody or an antigen-binding fragment thereof. The present invention also provides a nucleic acid encoding the isolated PD-L1 binding molecule, an expression vector or host cell comprising the nucleic acid, and a pharmaceutical composition or kit comprising the PD-L1 binding molecule.
    Type: Application
    Filed: October 30, 2020
    Publication date: January 5, 2023
    Inventors: Chao Kong, Guojun Lang, Qi Wu, Chanjuan Liu, Run Yan, Xintian Yan, Lunmei Tan
  • NOVEL CLDN18.2 BINDING MOLECULE
    Publication number: 20220396616
    Abstract: Disclosed is a novel CLDN18.2 binding molecule. Also disclosed are a nucleic acid molecule encoding the CLDN18.2 binding molecule, an expression vector and a host cell for expressing the CLDN18.2 binding molecule. Further disclosed are a method for producing the CLDN18.2 binding molecule and use thereof.
    Type: Application
    Filed: May 21, 2020
    Publication date: December 15, 2022
    Inventors: Yongcong Tan, Guojun Lang, Chao Kong, Chanjuan Liu, Min Deng, Qi Wu, Jing Zhang, Wenhai Zhang, Baoguo Fan